Contrast media
Providers may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and OTC monograph drugs thanks to language in a a federal FY 2023 spending law.

340B Pricing May Be Coming to Contrast Agents, Radiopharmaceuticals, and OTC Monograph Drugs

Health care providers in the coming months may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and so-called “OTC monograph” drugs thanks to language tucked into the massive fiscal year 2023 federal spending bill signed into law Dec. 29.

McDermott Will & Emery attorneys Emily Cook and Anisa Mohanty brought the provision to light in a Feb. 2 blog post.

Health care providers in the coming months may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and so-called “OTC monograph” drugs thanks to language tucked into the massive fiscal year 2023 federal spending bill signed into law Dec. 29.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer